Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Atomoxetine Hydrochloride is a non-stimulant medication primarily prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults. Chemically known as N-methyl-3-phenyl-3-(o-tolyl)-propylamine hydrochloride, its molecular formula is C₁₇H₂₁NO·HCl, and it bears the CAS Registry Number 109516-27-8. Unlike traditional stimulant treatments such as methylphenidate or amphetamines, atomoxetine functions selectively as a norepinephrine reuptake inhibitor (NRI). By blocking the presynaptic norepinephrine transporter, it increases the concentration of norepinephrine in the prefrontal cortex, thereby enhancing attention, impulse control, and executive function without the euphoric effects associated with stimulants. This unique mechanism makes it particularly valuable for patients who do not respond well to stimulants, have a history of substance abuse, or experience severe side effects from other therapies.
The drug is available commercially under brand names like Strattera and is administered orally once or twice daily due to its long half-life. Clinical studies have demonstrated significant efficacy in reducing core ADHD symptoms, including hyperactivity, impulsivity, and inattention, often providing sustained symptom relief throughout the day. While generally well-tolerated, common adverse effects may include nausea, dry mouth, decreased appetite, fatigue, and potential mood changes. Rare but serious risks involve hepatotoxicity and suicidal ideation in pediatric populations, necessitating careful monitoring by healthcare providers during initial therapy phases. Beyond its primary indication, off-label uses are occasionally explored for depression or anxiety disorders, though evidence remains limited. As a non-controlled substance in many jurisdictions, atomoxetine offers a safer alternative regarding misuse potential compared to controlled stimulants. Its development marked a pivotal advancement in psychiatric pharmacology, expanding treatment options for millions globally. Ongoing research continues to investigate optimized dosing strategies and long-term safety profiles to further refine its clinical application. Overall, Atomoxetine Hydrochloride represents a cornerstone therapy in modern ADHD management, balancing efficacy with a favorable safety profile for diverse patient demographics.